NEW YORK (GenomeWeb News) — Abbott has obtained a non-exclusive license to use Rubicon Genomics' MethylPlex methylation-detection technology, which it will use to develop in vitro diagnostics that detect presence or risk of prostate, bladder, and colon cancer, Rubicon said today.

The deal, which was struck as part of an ongoing agreement between the two companies, also grants Abbott a non-exclusive license to use the MethylPlex for screening applications with other diseases, and options to colon cancer biomarkers that it co-developed with Rubicon.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.